Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immunomedics Inc (IMMU)

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,873,690
  • Shares Outstanding, K 230,900
  • Annual Sales, $ 300 K
  • Annual Income, $ -357,190 K
  • 60-Month Beta 3.38
  • Price/Sales 26,980.08
  • Price/Cash Flow N/A
  • Price/Book 39.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.33
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.43
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +17.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.58 +21.50%
on 04/28/20
35.47 -5.53%
on 05/26/20
+5.18 (+18.28%)
since 04/27/20
3-Month
8.80 +280.80%
on 04/03/20
35.47 -5.53%
on 05/26/20
+17.84 (+113.92%)
since 02/27/20
52-Week
8.80 +280.80%
on 04/03/20
35.47 -5.53%
on 05/26/20
+18.71 (+126.42%)
since 05/24/19

Most Recent Stories

More News
DLA Piper advises Immunomedics in its US$483 million follow-on offering

, /PRNewswire/ -- DLA Piper represented Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, in its recent follow-on offering of common stock.

IMMU : 32.96 (-3.34%)
Is Immunomedics (IMMU) Stock Outpacing Its Medical Peers This Year?

Is (IMMU) Outperforming Other Medical Stocks This Year?

IMMU : 32.96 (-3.34%)
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

AZN : 51.41 (-3.20%)
PFE : 37.39 (-0.27%)
MRK : 76.83 (-0.56%)
LLY : 145.52 (-1.65%)
MYGN : 14.13 (-0.98%)
IMMU : 32.96 (-3.34%)
IBB : 127.85 (-2.26%)
CNCR : 26.00 (-2.59%)
XBI : 100.63 (-2.82%)
PBE : 56.44 (-1.62%)
Immunomedics to Present New Trodelvy(TM) Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting

Immunomedics, Inc., (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its recently FDA-approved ADC,...

IMMU : 32.96 (-3.34%)
Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss

Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.

IMMU : 32.96 (-3.34%)
SGEN : 144.50 (-4.77%)
ABBV : 90.02 (-0.76%)
RETA : 154.94 (-1.79%)
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q1 Loss

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

AZN : 51.41 (-3.20%)
SPPI : 2.96 (-1.00%)
IMMU : 32.96 (-3.34%)
SGEN : 144.50 (-4.77%)
BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance

BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.

ENDP : 3.87 (+1.04%)
IMMU : 32.96 (-3.34%)
BDSI : 4.83 (-1.02%)
SGEN : 144.50 (-4.77%)
Arena Pharmaceuticals (ARNA) Q1 Loss Narrower Than Expected

Arena Pharmaceuticals (ARNA) beats bottom-line estimates in the first quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

UTHR : 116.32 (-1.80%)
IMMU : 32.96 (-3.34%)
ARNA : 55.59 (-2.32%)
SGEN : 144.50 (-4.77%)
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q1 revenues increase year over year.

RHHBY : 43.0100 (-2.54%)
IMMU : 32.96 (-3.34%)
SRPT : 152.49 (-1.01%)
SGEN : 144.50 (-4.77%)
Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus

Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.

RHHBY : 43.0100 (-2.54%)
MRK : 76.83 (-0.56%)
IMMU : 32.96 (-3.34%)
NVS : 83.94 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade IMMU with:

Business Summary

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized...

See More

Key Turning Points

2nd Resistance Point 35.99
1st Resistance Point 35.05
Last Price 32.96
1st Support Level 33.58
2nd Support Level 33.05

See More

52-Week High 35.47
Last Price 32.96
Fibonacci 61.8% 25.28
Fibonacci 50% 22.14
Fibonacci 38.2% 18.99
52-Week Low 8.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar